The GI Effects® Comprehensive Stool Profile is a group of advanced stool tests that provide immediate, actionable clinical information for the management of gastrointestinal health. Utilizing cutting-edge technologies and biomarkers, this profile offers valuable insight into digestive function, intestinal inflammation, and the intestinal microbiome.
Genova Diagnostics is excited to announce an added level of enhanced clinical utility to GI Effects reporting. New enhancements make interpretation quicker and easier to prioritize treatment and assess microbiome status.
The report will now synthesize findings by integrating a novel, proprietary scoring system. These Functional Imbalance Scores will help direct targeted therapeutic recommendations with support options included on the front page of the report. Clinicians can prioritize test findings and treatment based on score severity and can track scores over time. Biomarkers are grouped and scored in 5 key areas relating to GI function:
Genova is the first laboratory to introduce an Inflammation-Associated Dysbiosis score and a Methane Dysbiosis score by incorporating our latest, published microbiome data analysis.1 These new patterns of dysbiosis can help differentiate treatment interventions. Additionally, we provide new graphics to better understand commensal bacteria patterns. Information about the patient's microbiome is organized into 3 areas:
We invite you to download the GI Effects Sample Report and listen to the The Lab Report Podcast episode introducing you to the new, improved report!
Learn more about Genova's Comprehensive GI Testing Value.
The GI Effects® Comprehensive Stool Profile is an advanced stool test that provides immediate, actionable clinical information for the management of gut health. Utilizing cutting-edge technologies and premier biomarkers, this ground-breaking stool test offers valuable insight into digestive function, gut inflammation, and the gut microbiome — areas affecting not only GI health, but overall health as well.
Gastrointestinal function is critical for good health. Emerging evidence in the scientific literature has associated gut microbiome status with a wide variety of common illnesses.
The GI Effects Comprehensive Stool Profile can reveal important information about the root cause of many common gastrointestinal symptoms such as gas, bloating, indigestion, abdominal pain, diarrhea, and constipation. This stool analysis utilizes biomarkers such as fecal calprotectin to differentiate between Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS).4,5 In addition, Genova's GI Effects test can be used to evaluate patients with a clinical history that suggests a gastrointestinal infection or dysbiosis.
Gut microbes are codependent with one another and with their human host, and the health of one affects the other. A sizeable volume of research associates a dysbiotic, or imbalanced gut microbiome with multiple disease states both within and outside of the GI tract.2,3 The diverse metabolic activities of the microbiome ultimately impact the human host, and the activities of the human host ultimately affect the health of their microbiome.
The biomarkers on the GI Effects Comprehensive Profile reflect the 3 key functions of gut health arranged in the "DIG" format: Digestion/Absorption, Inflammation/Immunology, and the Gut Microbiome:
A structured fecal biomarker panel offers the advantage of assessing multiple functional areas that may be contributing to symptoms. For example, diarrhea could stem from multiple causes including pancreatic exocrine insufficiency, inflammation, food allergies, or the presence of a pathogenic or potentially pathogenic organism. A positive result on one or more fecal biomarker tests may guide therapy, either by suggesting a treatable alternative diagnosis or by eliminating a diagnosis from further consideration. The latter allows individualized targeted treatment to be redirected to more likely diagnoses.6,7
GI Effects® represents the best technical platform available to assess the gut microbiome, combining:
The test report findings are synthesized into a results overview that helps the clinician to prioritize findings with functional imbalance scores and therapeutic support options. Furthermore, Genova summarizes the status of the patient's commensal bacteria levels with clinically actionable data.
The GI Effects Stool Profile biomarkers provide comprehensive information for the development of strategic interventions. Symptoms often improve as identified functional imbalances and inadequacies become normalized through targeted dietary, lifestyle, and supplementation therapeutics.
Test Type: Stool Test
Analyte List |
---|
Acetate % |
Akkermansia muciniphila |
Anaerotruncus colihominis |
Bacteriology |
Bacteroides vulgatus |
Bacteroides-Prevotella group |
Barnesiella spp. |
Beta- glucuronidase |
Bifidobacterium longum |
Bifidobacterium spp. |
Butyrivibrio crossotus |
Calprotectin |
Cholesterol |
Clostridium spp. |
Collinsella aerofaciens |
Color |
Consistency |
Coprococcus eutactus |
Desulfovibrio piger |
Eosinophil Protein X (EPX) |
Escherichia coli |
Faecalibacterium prausnitzii |
Fecal Fat (Total) |
Fecal Occult Blood |
Fecal sIgA |
Firmicutes/Bacteroidetes (F/B Ratio) |
Fusobacterium spp. |
Lactobacillus spp. |
Long Chain Fatty Acids |
Methanobrevibacter smithii |
Mic Sensitivities, Yeast or Bacteria |
Microscopic Exam Results |
Mycology (Yeast/Fungi) |
Odoribacter spp. |
Other Biomarkers |
Oxalobacter formigenes |
Pancreatic Elastase 1 |
Parasitology |
Phospholipids |
Prevotella spp. |
Products of Protein Breakdown (Total) (Valerate+Isobutyrate+Isovalerate) |
Propionate %. |
Pseudoflavonifractor spp. |
Roseburia spp. |
Ruminococcus spp. |
SCFA (Total) (Acetate, n-Butyrate, Propionate) |
Triglycerides |
Veillonella spp. |
n-Butyrate % |
n-Butyrate Concentration |
Specimen Requirements |
---|